CD180 and myeloid sarcoma: To bridge our findings to clinical translation, future studies will prioritize validation of NGP, HIST1H2BJ, CD180, PBLD1, MBNL3, and F10 in longitudinal EAE models and human MS lesion to assess their temporal dynamics during disease progression and remission.